Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma &amp; Immunology

Carter, Melody C.; Metcalfe, Dean D.; Matito, Almudena; Escribano, Luís; Butterfield, Joseph H.; Schwartz, Lawrence B.; Bonadonna, Patrizia; Zanotti, Roberta; Triggiani, Massimo; Castells, Mariana; Brockow, Knut

doi:10.1016/j.jaci.2018.10.063

Cited by 61 publications

(98 citation statements)

References 152 publications

(225 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While allergic reactions to foods and drugs have been reported in cMCD, the primary trigger for IgE-mediated severe, even fatal, anaphylactic reactions remains Hymenoptera stings. 17,18 In general, VIT induces protection from severe sting reactions in HVA patients during and after discontinuation of therapy. [19][20][21][22] Nevertheless, there have been controversies regarding its safety and efficacy in patients with cMCD.…”

Section: Discussionmentioning

confidence: 99%

Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection

Jarkvist

Salehi

Akin

et al. 2019

Allergy

View full text Add to dashboard Cite

Clonal mast cell disorders (cMCD) comprise systemic mastocytosis (SM) and monoclonal mast cell activation syndrome (MMAS). 1,2 Common to these two conditions is the presence of mast cell (MC) clonality, as reflected in a mutation in codon 816 of KIT and/or occurrence of immunophenotypically aberrant MCs expressing CD25. 3 In patients with MMAS, the WHO criteria for SM are not fully met. 3 Anaphylaxis is a well-known feature of cMCD; particularly, venom allergy represents an increased risk of severe, even fatal, sting anaphylaxis in these patients. 4,5 Although the overall prevalence of Hymenoptera venom-induced anaphylaxis (HVA) is approximately 25% in patients with SM, 6 the underlying reason(s) for this association remains elusive. The aggravated risk of severe HVA might be due to increased MC burden, perivascular aggregation of MCs and an amplified IgE reaction due to the presence of D816V KIT mutation. 7 These findings stress the importance of

show abstract

Section: Discussionmentioning

confidence: 99%

Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection

Jarkvist

Salehi

Akin

et al. 2019

Allergy

View full text Add to dashboard Cite

show abstract

“…In the rare cases in which a safe alternative cannot be identified, when antifungals are needed, desensitization can be performed, as it is described in amphotericin B and voriconazole [175,176]. 8. Heparins, anticoagulant drugs, Insulin and antidiabetic drugs.…”

Section: Tetraciclinesmentioning

confidence: 99%

Spanish Society of Allergology and Clinical Immunology (SEAIC) Vision of Drug Provocation Tests

Audicana

Ortega

Lobera

et al. 2021

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

The controlled drug exposure test (DPT) is currently considered the gold standard for the diagnosis of drug allergy. Drug-induced adverse reactions (ADRs) are a growing reason for consultation in both primary and specialized care. Allergology consultations in Spain are the ones that usually study these ADRs and rule out immunological mechanisms involved in up to 90% of the cases consulted. An adequate approach to these cases has an obvious impact on the costs and efficacy of the treatments required by other specialists, so that if we did not use DPTs, patients would require more expensive, more toxic and less effective treatments in most of the cases. In recent years, a large number of new drugs have been developed and this document is intended to be a practical guide in the management of PDT with the vision of the Spanish Allergology Society. Diagnostic work begins with a detailed history of the patient. Skin tests are only useful for some medications, and in most cases the diagnosis can only be confirmed by DPT. Although there is usually cross-reactivity, DPTs can confirm the diagnosis and also help to find a tolerable alternative drug. The individual management of patients in a programmed way, taking into account both the type of drug to be studied and the patient's comorbidities, usually allows a solution to be found for the majority of patients.

show abstract

“…Triggers of anaphylaxis in include Hymenoptera venom, drugs and food. Idiopathic anaphylaxis can also occur 33 …”

Section: Clinical Features and Histopathologymentioning

confidence: 99%

“…In children with mastocytosis, vaccination can potentially induce anaphylaxis and exacerbate mediator‐derived symptoms, such as generalised flushing, pruritus, urticaria/angioedema, bullous lesions or gastrointestinal symptoms 33 …”

Section: Clinical Features and Histopathologymentioning

confidence: 99%

Cutaneous mastocytosis: A dermatological perspective

Raimondo¹,

Duca²,

Silvaggio³

et al. 2020

Aust J Dermatology

View full text Add to dashboard Cite

Mastocytosis is a rare disease characterised by expansion and collection of clonal mast cells in various organs including the skin, bone marrow, spleen, lymph nodes and gastrointestinal tract. The prevalence of mastocytosis has been estimated to be one in 10 000, while the estimated incidence is one per 100 000 people per year. Cutaneous mastocytosis is classified into (i) maculopapular cutaneous mastocytosis, also known as urticaria pigmentosa; (ii) diffuse cutaneous mastocytosis; and (iii) mastocytoma of the skin. In adults, cutaneous lesions are usually associated with indolent systemic mastocytosis and have a chronic evolution. Paediatric patients, on the contrary, have often cutaneous manifestations without systemic involvement and usually experience a spontaneous regression. Diagnosis of cutaneous mastocytosis may be challenging due to the rarity of the disease and the overlap of cutaneous manifestations. This short review describes pathogenesis and clinical aspects of cutaneous mastocytosis with a focus on diagnosis and currently available therapies.

show abstract

Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology

Cited by 61 publications

References 152 publications

Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection

Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection

Spanish Society of Allergology and Clinical Immunology (SEAIC) Vision of Drug Provocation Tests

Cutaneous mastocytosis: A dermatological perspective

Contact Info

Product

Resources

About